(Total Views: 377)
Posted On: 06/05/2021 2:03:05 AM
Post# of 145247
I'm guessing you're talking about the drug LYT-100 which is a MAP kinase inhibitor. As I noted in a previous post it would affect the complement pathway, but not the classical or alternative. It should lower some of the effects of longhaulers but having a lesser downregulation of cytokines I doubt it can stop longhaulers as leronlimab may be able to do.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)